LMRI PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

LMRI ▼ -13.04% at T+5d

SHORT call ✓ call won +13.04% · α vs SPY +11.89% · entry $8.05 → $7.00

Next anchor: T+20d in 8h

Currently $8.65 · -7.45% from $8.05 entry (call sign-flipped)

Entry anchored
May 12, 03:59 PM ET
via Databento tick

T+1d

0.00%

call 0.00% · α -0.00%

$8.05

settled 28d ago

T+5d

-13.04%

call +13.04% · α +11.89%

$7.00

settled 22d ago

T+20d

—

call — · α —

—

in 8h

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Lumexa Imaging reported Q1 2026 GAAP EPS of $0.02, a massive miss vs the $0.12 consensus, and revenue of $252.5M slightly above the $251.2M estimate (+0.5%). The company swung to a net profit of $1.7M from a -$7.7M loss a year ago, but the headline EPS miss and flat adjusted EBITDA growth ($51.2M vs $51.0M) overshadow the revenue beat. Management reiterated full-year 2026 guidance, but the Street will focus on the earnings shortfall and the lack of upward revision despite the 'strong' volume narrative.

Key Financial Metrics

Guidance

$1.045B-$1.097B

maintained

Free Cash Flow

-$2.4M

Actionable Insight

The massive GAAP EPS miss (-83%) will dominate trading despite the revenue beat and profitability improvement. With guidance unchanged and Adj. EBITDA flat, there is no catalyst for upside. Watch for analyst downgrades and potential selling pressure at open. The reiterated guidance provides a floor but no reason to buy into weakness.

Key Facts

GAAP EPS $0.02 vs consensus $0.12 — a 83% miss
Revenue $252.5M vs consensus $251.2M — in-line (+0.5%)
Adjusted EPS $0.18 vs $0.04 a year ago, but Street consensus was $0.12 GAAP
Net income $1.7M vs net loss -$7.7M in Q1 2025
Adjusted EBITDA $51.2M flat vs $51.0M YoY; margin 20.3%
Full-year 2026 guidance reiterated: revenue $1.045-$1.097B, Adj. EBITDA $234-$242M, Adj. EPS $0.71-$0.77
Same-center advanced volume growth 5.6%; total procedures +1.3% consolidated, +2.5% system-wide
Stock-based compensation surged to $12.3M from $6.4M YoY, inflating adjusted metrics
Interest expense halved to $16.3M from $29.8M YoY, aiding net income swing

Financial Impact

EPS miss of $0.10 vs consensus on $252.5M revenue; flat Adj. EBITDA YoY; reiterated guidance provides no upside catalyst

epsnet incomeadjusted ebitdarevenue

Risk Factors

EPS miss of this magnitude (-83%) could trigger sharp sell-off and analyst downgrades
Flat Adj. EBITDA growth despite revenue growth suggests cost pressures or mix shift
Stock-based compensation doubling to $12.3M raises questions about shareholder dilution and expense discipline
Reiterated guidance with no upward revision despite 'strong' volume growth may disappoint growth investors

Market Snapshot

Exchange

Nasdaq

Sector

Services-Medical Laboratories

Analyst Consensus

93% bullish (14 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3293409

2 reports for LMRI

T+1T+5T+20T+60

Filters

Reports for LMRI — sortable, filterable
	Type				Now
May 12, 2026 28d ago	8-K NEUTRAL ★ 4/10	$8.05 $7.00	▼ −13.04%	▼ −11.89%	$8.65 (+7.45%)
May 12, 2026 28d ago	Press Release BEARISH ★ 7/10	$8.05 $7.00	▲ +13.04%	▲ +11.89%	$8.65 (−7.45%)

US Market Status

Market Closed — Opens Thu (9h 38m)

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access